Drug Profile
Epoetin alfa - Alkermes/Johnson & Johnson
Alternative Names: Epoetin alfa - ProLease; Epoetin alpha - Alkermes/Johnson & Johnson; Epoetin alpha - ProLease; r-HuEPO α - Alkermes/Johnson & Johnson; Recombinant human erythropoietin alfa - Alkermes/Johnson & Johnson; Recombinant human erythropoietin alpha - Alkermes/Johnson & JohnsonLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Kirin-Amgen
- Developer Alkermes; Johnson & Johnson
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 19 Jun 2000 Discontinued-I for Anaemia in USA (SC)
- 25 Nov 1998 Phase-I clinical trials for Anaemia in USA (SC)
- 09 Jul 1998 Preclinical development for Anaemia in USA (SC)